Overview

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

Status:
Completed
Trial end date:
2017-07-21
Target enrollment:
0
Participant gender:
All
Summary
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Avanir Pharmaceuticals
Treatments:
Dextromethorphan
Criteria
Inclusion Criteria:

- Patients who meet DSM-IV-TR diagnostic criteria for schizophrenia using the M.I.N.I.
version 6.0.

- Patients must meet PANSS criteria

- Patients currently receiving atypical antipsychotics are eligible provided they are on
a stable dose

Exclusion Criteria:

- Patients with current major depressive disorder (MDD)

- Patients with extrapyramidal syndrome secondary to their ongoing antipsychotic
medication

- Patients currently using anticholinergic medications

- Recent in-patient hospitalization